由Prevotella copri及其代谢物引起的Protocatechuic酸减弱的炎症
Jiatai Gong1, Siqi Ma1, Hongkun Xiang1
1Yuelushan Laboritory, Hunan Agricultural University, Changsha, China.
Virulence
|December 24, 2025
概括
甲基甲酸 (PCA) 减轻了猪仔中Prevotella copri引起的炎症和肠道屏障损伤. 通过减少炎症反应和增强肠道完整性,PCA提高了生长性能.
科学领域:
- 动物营养 动物营养
- 肠道微生物群研究 研究
- 免疫学 免疫学 免疫学
背景情况:
- 肠道微生物群影响宿主免疫力,并由植物化学物质调节.
- 普雷沃特拉·科普里 (P. copri) 与炎症有关.
- 原酸 (PCA) 显示出潜在的保护作用.
研究的目的:
- 调查P.copri影响小猪生长和肠道健康的机制.
- 评估PCA在抵消P.copri诱导的负面影响方面的有效性.
- 为了确定参与炎症的关键P. copri代谢物.
主要方法:
- 一个为期28天的养试验,有108只小猪被分配到三个组:基底食,基底食+P.copri,或基底食+P.copri+PCA.
- 测量生长性能 (体重,ADG,F/G),血清炎症细胞因子 (IL-2,IL-8) 和肠道紧结蛋白表达.
- 使用MODE-K细胞进行体外实验,以评估P.copri代谢物和PCA对炎症反应的影响.
主要成果:
- 补充P.copri降低了最终体重和平均每日增量 (ADG),增加了料增量比 (F/G),提高了血清IL-2和IL-8水平,并降低了肠道紧结蛋白表达.
- 补充PCA显著改善了ADG,抑制了炎症,并增强了肠道完整性.
- 在体外研究中确定了氨酸,醇-3-化物和N-甲素作为P. copri的代谢物,诱导炎症并降低紧密结合蛋白的调节,PCA显示剂量依赖的衰减.
结论:
- P. copri通过诱导炎症和损害肠道屏障,对小猪生长和肠道健康产生负面影响.
- 通过抑制炎症和恢复肠道完整性,PCA有效地抵消P.copri的不良影响.
- PCA代表了一种有前途的策略,可以改善与P. copri. 挑战的断奶小猪的生长性能.
相关概念视频
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
889
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
889
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
812
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
812
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.0K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.0K
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Peptic Ulcer Disease II: Pathophysiology
1.8K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K

